Journal
JOURNAL OF INVESTIGATIVE DERMATOLOGY
Volume 138, Issue 1, Pages 58-67Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jid.2017.07.839
Keywords
-
Categories
Funding
- French Health Ministry (PHRC, Programme Hospitalier de Recherche Clinique)
- Assistance Publique-Hopitaux de Paris (Departement de la Recherche Clinique et du Developpement, Clinical Research and Development Department)
- Novartis
- INSERM
- Fondation ARC pour la recherche sur le cancer (Poste Accueil)
Ask authors/readers for more resources
Mutated oncogenic KIT is a therapeutic target in melanoma. We conducted a multicenter phase II trial on the KIT inhibitor nilotinib in patients with unresectable melanoma harboring KIT alteration. The primary endpoint was the response rate (complete response or partial response following Response Evaluation Criteria in Solid Tumors criteria) at 6 months. Pharmacodynamic studies using KIT sequencing, qPCR array, and immunostaining of downstream KIT effectors were performed during treatment. Twenty-five patients were included and received 400 mg oral nilotinib twice daily. At 6 months, nilotinib induced tumor response in four patients. The best overall response rate was 20% and the disease control rate was 56%, limited to patients harboring exon 11 or 13 mutations. Four patients exhibited durable response, including three persisting (3.6 and 2.8 years for two patients with stage IIIC and 2.5 years for one with IVM1b melanoma). A reduction in signal transducer and activator of transcription (STAT) 3 phosphorylation and its effectors (BCL-2, MCL-1) in tumors during follow-up was significantly associated with clinical response. In the KIT-mutated melanoma cell line M230, nilotinib reduced STAT3 signaling and STAT inhibitors were as efficient as KIT inhibitors in reducing cell proliferation. Our study evidences a significant association between STAT3 inhibition and response to nilotinib, and provides a rationale for future research assessing STAT inhibitors in KIT-mutated melanoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available